Array's pain drug clears PhII 'high hurdle' but QT signs raise some flags
This article was originally published in Scrip
Executive Summary
Array BioPharma's CEO was on the defensive on 1 August as the company's stock fell 15.2% on the company's news released after the market closed a day earlier that ARRY-797 provided statistically significant pain relief in a Phase II clinical trial; was just as effective as, but not superior to, oxycodone ER; and caused mild prolongations of the QTc interval in some patients, but not at levels that indicate cardiac arrhythmia.
You may also be interested in...
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.
Pharma On The Hunt For Oncology Partners Across Modalities
The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.